Pulmonx Corp. (LUNG): Price and Financial Metrics


Pulmonx Corp. (LUNG): $39.08

0.09 (+0.23%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

LUNG Stock Price Chart Interactive Chart >

Price chart for LUNG

LUNG Price/Volume Stats

Current price $39.08 52-week high $69.48
Prev. close $38.99 52-week low $35.81
Day low $38.40 Volume 381,552
Day high $39.39 Avg. volume 347,359
50-day MA $39.30 Dividend yield N/A
200-day MA $48.00 Market Cap 1.43B

Pulmonx Corp. (LUNG) Company Bio


Pulmonx Corp. provides interventional pulmonology, planning tools, and treatments for obstructive lung diseases. It carries out its operations in the following geographical locations: Europe, Middle East and Africa (EMEA), Asia Pacific, Other International, and United States. It offers the Zephyr Endobronchial Valve, an implantable device used to occlude all airways feeding the hyperinflated lobe of a lung that is most diseased with emphysema. It also offers StratX Lung Analysis, a platform designed to treat severe emphysema, and the Chartis Assessment System, a pulmonary assessment system. The company was founded by Rodney C. Perkins and is headquartered in Redwood City, CA.


LUNG Latest News Stream


Event/Time News Detail
Loading, please wait...

LUNG Latest Social Stream


Loading social stream, please wait...

View Full LUNG Social Stream

Latest LUNG News From Around the Web

Below are the latest news stories about Pulmonx Corp that investors may wish to consider to help them evaluate LUNG as an investment opportunity.

3 Healthcare Stocks That Might Skyrocket When COVID Is Over

Stocks of biotech companies fighting COVID-19 have been great investments over the last two years. What stocks might zoom higher when the pandemic is over?

Yahoo | September 7, 2021

Pulmonx to Present at Upcoming September Investor Conferences

REDWOOD CITY, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx) today announced the company will be participating in fireside chats at two upcoming virtual investor conferences. Pulmonx management is scheduled to participate in the 2021 Virtual Wells Fargo Healthcare Conference on Thursday, September 9, 2021 at 7:00am PT / 10:00am ET and the Morgan Stanley 19 th Annual Global Healthcare Conference on Monday, September 13, 2021 at 1:15pm PT / 4:15pm ET.

Intrado Digital Media | August 26, 2021

Pulmonx Announces Anthem Blue Cross Blue Shield Now Provides Coverage for Severe COPD/Emphysema Treatment

REDWOOD CITY, Calif.--(BUSINESS WIRE)---- $LUNG #COPD--Positive Coverage Policy Gives Additional 34 Million People Access to Treatment with the Zephyr® Valve, a Minimally Invasive Treatment Option

Business Wire | August 20, 2021

Pulmonx Corporation (LUNG) Q2 2021 Earnings Call Transcript

LUNG earnings call for the period ending June 30, 2021.

The Motley Fool | August 4, 2021

Pulmonx Reports Second Quarter 2021 Financial Results

REDWOOD CITY, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx or the "Company"), a global leader in minimally invasive treatments for severe lung disease, today reported financial results for the second quarter ended June 30, 2021.

Intrado Digital Media | August 3, 2021

Read More 'LUNG' Stories Here

LUNG Price Returns

1-mo 4.52%
3-mo -7.37%
6-mo -26.12%
1-year N/A
3-year N/A
5-year N/A
YTD -43.38%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.5642 seconds.